Table 1.

Antiherpesvirus activity of the combination H2G plus MPA

Virus (strain)EC50(μg/ml)a of H2G
AloneIn combination with MPA at indicated concn
10 μg/ml2.5 μg/ml1.0 μg/ml0.25 μg/ml
HSV-1 (KOS)5.3 ± 3.40.06 ± 0.050.16 ± 0.180.24 ± 0.170.35 ± 0.33
HSV-2 (G)11.3 ± 2.90.07 ± 0.020.24 ± 0.220.3 ± 0.171.6 ± 0.8
TK HSV-1 (B2006)>1000.04 ± 0.030.08 ± 0.010.25 ± 0.210.8 ± 0.17
VZV (OKA)0.0043 ± 0.0040.0053 ± 0.00490.0007 ± 0.00060.0008 ± 0.00060.0006 ± 0.0003
VZV (YS)0.01 ± 0.0070.0068 ± 0.0080.0014 ± 0.00120.0008 ± 0.00050.0007 ± 0.0004
TK VZV (07-1)4.6 ± 3.70.08 ± 0.070.31 ± 0.260.33 ± 0.261.0 ± 1.3
TK VZV (YS-R)11.7 ± 11.70.35 ± 0.30.19 ± 0.130.29 ± 0.282.8 ± 3.5
  • a Concentration required to reduce virus-induced CPE by 50%. The EC50 for inhibition of HSV- or VZV-induced CPE by MPA was >10 μg/ml. Data are mean values ± standard deviations for three to eight separate determinations.